Recommended Loading Dose for Levetiracetam (Keppra)
The recommended loading dose for levetiracetam (Keppra) is 30 mg/kg IV administered over 15 minutes, with a maximum of 2,500 mg. 1
Dosing Guidelines by Clinical Context
Status Epilepticus
- Loading dose: 30 mg/kg IV over 15 minutes 1
- Maximum single dose: 2,500 mg 2
- Efficacy in status epilepticus: 73% seizure cessation rate 1
Routine Initiation (when oral administration is not feasible)
- Initial dose: 500 mg IV twice daily 2
- Titration: Increase by 500 mg twice daily every 2 weeks 2
- Maximum recommended maintenance dose: 1,500 mg twice daily (3,000 mg/day) 2
Administration Considerations
Infusion Parameters
- Standard infusion: Administer over 15 minutes 2
- Do not dilute prior to use 2
- Available in pre-mixed bags of 500 mg/100 mL, 1,000 mg/100 mL, and 1,500 mg/100 mL 2
Rapid Infusion Options
- Emerging evidence suggests that administration over 5 minutes appears safe and well-tolerated 3
- Rapid infusion may be beneficial in acute care settings requiring rapid attainment of therapeutic levels 3
Special Population Considerations
Renal Impairment
Dose adjustment required based on creatinine clearance 2:
- Normal (>80 mL/min): 500-1,500 mg every 12 hours
- Mild impairment (50-80 mL/min): 500-1,000 mg every 12 hours
- Moderate impairment (30-50 mL/min): 250-750 mg every 12 hours
- Severe impairment (<30 mL/min): 250-500 mg every 12 hours
Pharmacokinetics After Loading
- After a 1,500 mg IV infusion, peak plasma concentration (Cmax) reaches approximately 50.5 μg/mL 4
- Bioequivalence between IV and oral formulations has been established 4
- Steady state is reached within 48 hours of regular dosing 4
Oral Loading Alternative
When IV administration is not available, oral loading may be considered:
- Oral loading dose: 1,500 mg as a single dose 5
- Maintenance: Begin 500-1,000 mg twice daily starting 12 hours after loading 5
- Serum concentrations after oral loading: ~30 μg/mL at 1-2 hours post-dose 5
Common Adverse Effects with Loading Doses
- Somnolence (33% with IV vs 17% with placebo) 4
- Postural dizziness (25% with IV vs 0% with placebo) 4
- Generally well-tolerated with minimal serious adverse effects 3, 4, 5
Clinical Pitfalls to Avoid
Underdosing: Only 54% of patients achieve target serum levels with low doses (500 mg twice daily); higher doses (750-1,000 mg twice daily) are more than twice as likely to achieve optimal drug levels 6
Inadequate monitoring: Monitor for adverse effects including somnolence, dizziness, and behavioral changes 2
Abrupt discontinuation: Gradually withdraw levetiracetam to reduce the risk of increased seizure frequency and status epilepticus 2
Compatibility issues: Levetiracetam is physically compatible with lorazepam, diazepam, and valproate sodium for at least 24 hours, but compatibility with other antiepileptic drugs is not established 2
In summary, while the FDA-approved loading dose for levetiracetam is not explicitly stated in the package insert, clinical evidence supports a loading dose of 30 mg/kg IV (maximum 2,500 mg) administered over 15 minutes for patients requiring rapid initiation of therapy, particularly in status epilepticus.